Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 4
2013 1
2014 3
2015 1
2016 5
2017 2
2018 2
2019 1
2020 2
2021 1
2022 6
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies.
Recio F, Scalise CB, Loar P, Lumish M, Berman T, Peddada A, Kalashnikova E, Rivero-Hinojosa S, Beisch T, Nicosia B, Farmer T, Dutta P, Malhotra M, ElNaggar AC, Liu MC, Vaccarello L, Holloway RW. Recio F, et al. Among authors: elnaggar ac. Gynecol Oncol. 2024 Mar;182:63-69. doi: 10.1016/j.ygyno.2023.12.025. Epub 2024 Jan 22. Gynecol Oncol. 2024. PMID: 38262240 Free article.
Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
Friedman CF, D'Souza A, Bello Roufai D, Tinker AV, de Miguel M, Gambardella V, Goldman J, Loi S, Melisko ME, Oaknin A, Spanggaard I, Shapiro GI, ElNaggar AC, Panni S, Ravichandran V, Frazier AL, DiPrimeo D, Eli LD, Solit DB. Friedman CF, et al. Among authors: elnaggar ac. Gynecol Oncol. 2024 Feb;181:162-169. doi: 10.1016/j.ygyno.2023.12.004. Epub 2024 Jan 11. Gynecol Oncol. 2024. PMID: 38211393 Free article. Clinical Trial.
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
Randall LM, O'Malley DM, Monk BJ, Coleman RL, Gaillard S, Adams S, Duska LR, Dalton H, Holloway RW, Huang M, Chon HS, Cloven NG, ElNaggar AC, O'Cearbhaill RE, Waggoner S, Tarkar A, Striha A, Nelsen LM, Baines A, Samnotra V, Konstantinopoulos PA. Randall LM, et al. Among authors: elnaggar ac. Gynecol Oncol. 2023 Nov;178:161-169. doi: 10.1016/j.ygyno.2023.10.005. Epub 2023 Oct 25. Gynecol Oncol. 2023. PMID: 37890345 Clinical Trial.
Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up.
Lindskrog SV, Birkenkamp-Demtröder K, Nordentoft I, Laliotis G, Lamy P, Christensen E, Renner D, Andreasen TG, Lange N, Sharma S, ElNaggar AC, Liu MC, Sethi H, Aleshin A, Agerbæk M, Jensen JB, Dyrskjøt L. Lindskrog SV, et al. Among authors: elnaggar ac. Clin Cancer Res. 2023 Dec 1;29(23):4797-4807. doi: 10.1158/1078-0432.CCR-23-1860. Clin Cancer Res. 2023. PMID: 37782315 Free PMC article.
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Arend R, Dholakia J, Castro C, Matulonis U, Hamilton E, Jackson CG, LyBarger K, Goodman HM, Duska LR, Mahdi H, ElNaggar AC, Kagey MH, Liu A, Piper D, Barroilhet LM, Bradley W, Sachdev J, Sirard CA, O'Malley DM, Birrer M. Arend R, et al. Among authors: elnaggar ac. Gynecol Oncol. 2023 May;172:82-91. doi: 10.1016/j.ygyno.2023.03.013. Epub 2023 Mar 29. Gynecol Oncol. 2023. PMID: 37001446 Clinical Trial.
Clinical outcomes in patients with COVID-19 and gynecologic cancer: A society of gynecologic oncology COVID-19 and gynecologic cancer registry study.
Glaser GE, Lara OD, Pothuri B, Grimaldi CG, Prescott LS, Mastroyannis SA, Kim S, ElNaggar AC, Torres D, Conrad LB, McGree M, Weaver A, Huh WK, Cohn DE, Yamada SD, Fader AN. Glaser GE, et al. Among authors: elnaggar ac. Gynecol Oncol. 2022 Nov;167(2):146-151. doi: 10.1016/j.ygyno.2022.09.017. Epub 2022 Sep 23. Gynecol Oncol. 2022. PMID: 36154761 Free PMC article.
Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.
Hou JY, Chapman JS, Kalashnikova E, Pierson W, Smith-McCune K, Pineda G, Vattakalam RM, Ross A, Mills M, Suarez CJ, Davis T, Edwards R, Boisen M, Sawyer S, Wu HT, Dashner S, Aushev VN, George GV, Malhotra M, Zimmermann B, Sethi H, ElNaggar AC, Aleshin A, Ford JM. Hou JY, et al. Among authors: elnaggar ac. Gynecol Oncol. 2022 Nov;167(2):334-341. doi: 10.1016/j.ygyno.2022.09.004. Epub 2022 Sep 16. Gynecol Oncol. 2022. PMID: 36117009 Free article.
Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
Cadoo K, Simpkins F, Mathews C, Liu YL, Provencher D, McCormick C, ElNaggar AC, Altman AD, Gilbert L, Black D, Kabil N, Bennett J, Munley J, Aghajanian C. Cadoo K, et al. Among authors: elnaggar ac. Gynecol Oncol. 2022 Sep;166(3):425-431. doi: 10.1016/j.ygyno.2022.06.017. Epub 2022 Jul 5. Gynecol Oncol. 2022. PMID: 35803835 Free PMC article. Clinical Trial.
Molecular profiles of endometrial cancer tumors among Black patients.
Wilhite AM, Baca Y, Xiu J, Paladugu R, ElNaggar AC, Brown J, Winer IS, Morris R, Erickson BK, Olawaiye AB, Powell M, Korn WM, Rocconi RP, Khabele D, Jones NL. Wilhite AM, et al. Among authors: elnaggar ac. Gynecol Oncol. 2022 Jul;166(1):108-116. doi: 10.1016/j.ygyno.2022.04.014. Epub 2022 Apr 28. Gynecol Oncol. 2022. PMID: 35490034
31 results